Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2026 16:05 ET | Source: LeonaBio, Inc.

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations ...
April 23, 2026 16:05 ET | Source: LeonaBio, Inc.

LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer

Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast...
April 21, 2026 07:00 ET | Source: LeonaBio, Inc.

Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data

BOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high...
March 26, 2026 17:10 ET | Source: LeonaBio, Inc.

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer...